Publikationen 2026

30. Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia. Córdoba R, Stilgenbauer S, Ghia P, Tedeschi A, Roeker L, Rodriguez-Couso M, Mulligan SP, Nabhan SK, Rynne J, López-Fernández T.
Hemasphere. 2026 Feb 19;10(2):e70290. doi: 10.1002/hem3.70290. eCollection 2026 Feb.

29. Targeting mutant VHL-gene results in therapy response in metastatic clear cell carcinoma of rete testis. Melzer MK, Mattigk A, Gaidzik VI, Gaisa NT, Schwenke J, Zengerling F.
Urol Case Rep. 2026 Feb 16;65:103376. doi: 10.1016/j.eucr.2026.103376. eCollection 2026 Mar.

28. Impact of FMS-like tyrosine kinase 3 inhibitor maintenance on post-transplant outcomes in acute myeloid leukemia with FMS-like tyrosine kinase 3 mutations: a real-world German registry analysis highlighting sorafenib. Massoud R, Flossdorf S, Hanke F, Schroeder T, Bethge W, Zeiser R, Pabst C, Wulf G, Sala E, Hilgendorf I, Scheid C, Edinger M, Stölzel F, Blau IW, Stelljes M, Kobbe G, Platzbecker U, Bittenbring JT, Eder M, Fleischhauer K, Burchert A, Schmid C, Kröger N. Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300176. Online ahead of print.

27. Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia. Hartmann M, Schönung M, Rajak J, Maurer V, Hai L, Bauer K, Hakobyan M, Stäble S, Langstein J, Jardine L, Roelz R, Bohler S, Khabirova E, Maag AH, Vonficht D, Lebrecht D, Bernt KM, Tan K, Chen C, Alikarami F, Meyer J, Wang J, Boch T, Flore V, Lutsik P, Milsom MD, Raffel S, Buske C, Haas S, Haniffa M, Mallm JP, Behjati S, Bonder MJ, Fröhling S, Stieglitz E, Niemeyer CM, Hey J, Flotho C, Plass C, Erlacher M, Schlesner M, Lipka DB.
Blood Cancer Discov. 2026 Mar 4;7(2):306-330. doi: 10.1158/2643-3230.BCD-25-0246.

26. Patient characteristics and treatment outcomes in marginal zone lymphoma: results of the prospective German MZL registry.Grunenberg A, Schmelzle B, Gökeler J, Mund H, Viardot A, Dreyhaupt J, Nagel G, Reiser M, Gabrysiak T, Braulke F, Dunst J, Schlag R, Gaska T, Runde V, Kraemer D, Weber T, Mueller L, Johansson P, Ziske C, Hess G, Liersch R, Buske C.
Leukemia. 2026 Mar 6. doi: 10.1038/s41375-026-02869-7. Online ahead of print.

25. ULK4 and CDKN2A polymorphisms influence the risk of developing monoclonal gammopathy of undetermined significance. Sánchez-Maldonado JM, Macauda A, Cabrera-Serrano AJ, Thomsen H, Güler M, Horst RT, van Guelpen B, Vodicka P, Landi S, Chattopadhyay S, Ünal P, Ruiz-Durán L, Casabonne D, Goldschmidt H, Serin I, Carretero-Fernández M, Cabezudo E, Reyes-Zurita F, Norman AD, García-Sanz R, Capurso G, Hoffmann P, Pettersson-Kymmer U, Jiménez-Romera F, Rajkumar SV, Weinhold N, Vodickova L, Langer C, Stein A, Karismaz A, Moreno V, Nöthen MM, Jöckel KH, Tavano F, Martínez-López J, Kumar SK, Gutiérrez-Bautista JF, Basso D, Späth F, Benavente Y, Hildebrandt MAT, Schmidt B, Sevcikova T, Reis RMV, Li Y, López-Nevot MÁ, Netea MG, Campa D, Clay-Gilmour A, Slager SL, Hemminki K, Vachon CM, Försti A, Canzian F, Sainz J.
Int J Cancer. 2026 Mar 11. doi: 10.1002/ijc.70427. Online ahead of print.

24. Short and complex-Telomeres and genomes in CLL.Jebaraj BMC, Stilgenbauer S.
Br J Haematol. 2026 Mar 11. doi: 10.1111/bjh.70430. Online ahead of print.

23. Epidemiology, treatment patterns, and survival outcomes of patients with mantle cell lymphoma in Germany: a retrospective analysis of administrative claims data. Friedel H, Hennies N, Zschocke J, Hosseini SK, Bölz S, Bocuk D, Wilhelm S, Zaba O, Buske C.
Ann Hematol. 2026 Mar 13;105(4):173. doi: 10.1007/s00277-026-06915-3.

22. Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia. Simon F, Ligtvoet R, Fürstenau M, Langerbeins P, Fink AM, von Tresckow J, Cramer P, Kutsch N, Goede V, Poulsen CB, Illmer T, Müller L, Vehling-Kaiser U, Eckart M, Staber P, Tadmor T, Gregor M, Juliusson G, Thornton P, Sivcheva L, Loscertales J, Jentsch-Ullrich K, Hebart H, Levin MD, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Kater AP, Niemann CU, Fischer K, Robrecht S, Hallek M, Eichhorst B, Al-Sawaf O.
Leuk Lymphoma. 2026 Mar 17:1-7. doi: 10.1080/10428194.2026.2634939. Online ahead of print.

21. Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP. Cetin O, Kos I, Regitz E, Bewarder M, Rixecker TM, Tausch E, Schwarz EC, Jansky J, Lesan V, Schormann C, Neumann F, Loeffler M, Hallek M, Fischer K, Zöphel S, Staiger AM, Ott G, Christofyllakis K, Bittenbring JT, Poeschel V, Kaddu-Mulindwa D, Staber PB, Ligtvoet R, Robrecht S, Ziepert M, Schmitz N, Hoth M, Kessel C, Stilgenbauer S, Altmann B, Thurner L.
Blood Adv. 2026 Feb 24;10(4):1045-1050.

20. [A rare cause of otitis externa : Manifestation of myeloid sarcoma in the petrous bone]. Ihle V, Goldberg-Bockhorn E, Lemaitre E, Gaidzik VI, Hoffmann TK, Kuhn AS.
HNO. 2026 Feb 12. doi: 10.1007/s00106-026-01731-7. Online ahead of print. PMID: 41677805 German.

19. Corrigendum to "U-RT1 - A new model for Richter transformation" [Neoplasia Volume 23, Issue 1, January 2021, Pages 140-148]. Schmid T, Maier J, Martin M, Tasdogan A, Tausch E, Barth TFE, Stilgenbauer S, Bloehdorn J, Möller P, Mellert K.
Neoplasia. 2026 Feb 20;73:101292. doi: 10.1016/j.neo.2026.101292. Online ahead of print. PMID: 41722505

18. Results of brexucabtagene-autoleucel for patients with relapsed/refractory Mantle Cell Lymphoma in the routine setting in Germany and Switzerland. Simon L, Vucinic V, Rejeski K, Schubert ML, Aydilek E, Wagner-Drouet EM, Penack O, von Bonin M, von Tresckow B, Teichert M, Marks R, Pott C, Fehr M, Leng C, Schroers R, Koenecke C, Duell J, Stilgenbauer S, Mueller F, Hecker JS, Brunnberg U, Kroeger N, Kronfeld K, Theobald M, Ohler A, Schmidtmann I, Hess G, Dreger P.
Bone Marrow Transplant. 2026 Jan 16. doi: 10.1038/s41409-025-02789-7. Online ahead of print. PMID: 41545665 No abstract available.

17. Unravelling co-mutational patterns with prognostic implications in NPM1 mutated adult acute myeloid leukemia - a HARMONY study. Hernández-Sánchez A, Villaverde Ramiro Á, Sträng E, Turki AT, Abáigar M, Versluis J, Thomas I, Sobas M, Martínez Elicegui J, Castellani G, Benner A, Azibeiro R, Tettero JM, Mecklenbrauck R, Martínez-López J, Pratcorona M, Mills KI, Sanz G, Voso MT, Sören L, Röllig C, Thiede C, Metzeler KH, Döhner K, Heuser M, Haferlach T, Valk PJ, Russell N, Hernández-Rivas JM, Huntly B, Ossenkoppele G, Döhner H, Bullinger L.
Leukemia. 2026 Feb;40(2):418-428. Epub 2026 Jan 14.

16. Overactivation of Cdc42 GTPase Impairs the Cytotoxic Function of NK Cells From Old Individuals Towards Senescent Fibroblasts. Koroma AK, Singh K, Wang Y, Krug L, Haas P, Wlaschek M, Sakk V, Schuster T, Fürst D, Schrezenmeier H, Dheenadayalan RP, Stilgenbauer S, Walter L, Geiger H, Scharffetter-Kochanek K, Maity P.
Aging Cell. 2026 Feb;25(2):e70398. doi: 10.1111/acel.70398.

15. Prognostic impact of myelodysplasia-related gene mutations in FLT3-ITD-mutated acute myeloid leukemia. Mecklenbrauck R, Villaverde Ramiro A, Sträng E, Gabdoulline R, Martinez Elicegui J, Sobas M, Pleyer L, Turki A, Voso MT, Benner A, Hernández-Sánchez A, Tettero JM, Tur Gimenez L, Metzeler KH, Oñate G, Lehmann S, Huntly BJ, Thomas I, Thol FR, Heidel FH, Valk PJ, Döhner K, Haferlach T, Mills KI, Döhner H, Castellani G, Ossenkoppele GJ, Hernández-Rivas JM, Bullinger L, Heuser M.
Leukemia.  2026 Mar;40(3):622-629. Epub 2026 Feb 9.

14. Immune checkpoint inhibition increases antigen-specific T cell response in head and neck cancer. Schuler PJ, Oliveri F, Puntigam L, Six K, Kaißer C, Maier J, Laban S, von Witzleben A, Brunner C, Messerer DAC, Schrezenmeier H, Hoffmann TK, Goetz M, Greiner J.
Sci Rep. 2026 Feb 9;16(1):5583. 

13. The Landscape and Evolution of Clonal Hematopoiesis in Chronic Lymphocytic Leukemia. Al-Sawaf O, Locher BN, Christen F, Hablesreiter R, Rajamani A, Robrecht S, Zhang C, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Kopp K, Mertz ME, Fustero-Torre C, Kleo K, Seymour JF, Blombery P, Bullinger L, Chyla B, Jin HY, Jiang Y, Stilgenbauer S, Hallek MJ, Eichhorst BF, Langerbeins P, Fischer K, Damm F.
Blood. 2026 Mar 19;147(12):1323-1337.

12. A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm. Rampotas A, Aspa-Cilleruelo JM, Koster L, Avenoso D, Passweg J, Sala E, Robin M, Myhre AE, de Witte M, Nur E, Chevallier P, Schroeder T, Srour M, Chiusolo P, Salmenniemi U, Verbeek M, Finazzi MC, Castilla-Llorente C, Rubio MT, Sobieralski P, Sockel K, Alabdulkarim A, Drozd-Sokolowska J, Raj K, Battipaglia G, Czerw T, Polverelli N, Hernández-Boluda JC, McLornan DP.
Bone Marrow Transplant. 2026 Mar;61(3):333-340. Epub 2025 Dec 24.

11. 2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party. Cloos J, Valk PJM, Thiede C, Döhner K, Roboz GJ, Wood BL, Walter RB, Wang SA, Wierzbowska A, Wei AH, Wu D, Vergez F, Venditti A, van der Reijden BA, van de Loosdrecht AA, Tiong IS, Thol FR, Subklewe M, Roumier C, Reuvekamp T, Ravandi F, Preudhomme C, Plesa A, Othman J, Ossenkoppele GJ, Ofran Y, Mimoun A, Maurillo L, Majchrzak A, de Leeuw DC, Kern W, Kim DDHDH, Ikoma-Colturato MRV, Haaksma LH, Guzman ML, Feuring M, Depreter B, Czyz A, Bücklein VL, Baer C, Bachas C, Freeman SD, Buccisano F, Hourigan CS, Dillon RJ, Heuser M.
Blood. 2026 Mar 12;147(11):1147-1167.

10. Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia. Hartmann M, Schönung M, Rajak J, Maurer V, Hai L, Bauer K, Hakobyan M, Stäble S, Langstein J, Jardine L, Roelz R, Bohler S, Khabirova E, Maag AH, Vonficht D, Lebrecht D, Bernt KM, Tan K, Chen C, Alikarami F, Meyer J, Wang J, Boch T, Flore V, Lutsik P, Milsom MD, Raffel S, Buske C, Haas S, Haniffa M, Mallm JP, Behjati S, Bonder MJ, Frohling S, Stieglitz E, Niemeyer CM, Hey J, Flotho C, Plass C, Erlacher M, Schlesner M, Lipka DB.
Blood Cancer Discov. 2025 Dec 5. doi: 10.1158/2643-3230.BCD-25-0246. Online ahead of print.

9. Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP. Cetin O, Kos IA, Regitz E, Bewarder M, Rixecker TM, Tausch E, Schwarz EC, Jansky J, Lesan V, Schormann C, Neumann F, Loeffler M, Hallek MJ, Fischer K, Zophel S, Staiger AM, Ott G, Christofyllakis K, Bittenbring JT, Poeschel V, Kaddu-Mulindwa D, Staber PB, Ligtvoet R, Robrecht S, Ziepert M, Schmitz N, Hoth M, Kessel C, Stilgenbauer S, Altmann B, Thurner L.
Blood Adv. 2026 Feb 24;10(4):1045-1050.

8. Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia. Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M; CLL17 Trial Investigators.
N Engl J Med. 2026 Mar 12;394(11):1084-1096. Epub 2025 Dec 6.

7. Different immunotherapeutic combinations enhance specific T cell immune responses against leukemic cells, as well as leukemic progenitor cells, in acute myeloid leukemia. Greiner J, Schuler PJ, Schrezenmeier H, Weiss J, Bulach C, Goetz M, Guinn BA. 
Leukemia. 2026 Jan;40(1):130-137. Epub 2025 Oct 27.

6. Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients. Bill M, Eckardt JN, Döhner K, Röhnert MA, Rausch C, Metzeler KH, Spiekermann K, Stasik S, Wurm AA, Sauer T, Scholl S, Schnetzke U, Hochhaus A, Crysandt M, Brümmendorf TH, Krug U, Wörmann B, Einsele H, Hiddemann W, Görlich D, Sauerland C, Steffen B, Neubauer A, Burchert A, Schäfer-Eckart K, Berdel WE, Schliemann C, Krause SW, Hänel M, Hanoun M, Kaufmann M, Fransecky L, Braess J, Schetelig J, Middeke JM, Bullinger L, Heuser M, Thol F, Serve H, Baldus CD, Platzbecker U, Müller-Tidow C, Válka J, Šrámek J, Weinbergerova B, Mayer J, Dumas PY, Bertoli S, Delabesse E, Récher C, Pigneux A, Herold T, Ganser A, Döhner H, Bornhäuser M, Thiede C, Röllig C. 
Leukemia. 2026 Jan;40(1):63-71. Epub 2025 Oct 27.

5. Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Möhle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuß A, Göthert JR, Ernst T, Abu-Samra M, Höffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C. 
Leukemia. 2026 Feb;40(2):410-417. Epub 2026 Jan 12.

4. Phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia. Döhner H, Späth D, Saadati M, Fiedler W, Götze KS, Koller E, Westermann J, Vogel W, Heuser M, Lübbert M, Tischler HJ, Germing U, Teichmann LL, Fransecky L, Wölfler A, Nachbaur D, Hertenstein B, Schroers R, Martens UM, von Harsdorf S, Radsak MP, Aschauer G, Weißhaar S, Corbacioglu A, Schrade A, Gaidzik VI, Thol FR, Paschka P, Bullinger L, Benner A, Döhner K, Ganser A. 
Blood. 2026 Jan 5:blood.2025030722. doi: 10.1182/blood.2025030722. Online ahead of print.

3. First-line treatment for CLL in the era of targeted therapy. Davids MS, Stilgenbauer S, Tam CS.
Blood Cancer J. 2026 Jan 8;16(1):19.

2. Shifting clones: CLL evolution under pirtobrutinib treatment. Jebaraj BMC, Stilgenbauer S. 
Blood. 2026 Jan 1;147(1):3-4. doi: 10.1182/blood.2025031598

1. Overcoming BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia by Targeting PKCβ. Jebaraj BMC, Stilgenbauer S.
Blood Cancer Discov. 2026 Jan 12;7(1):21-24.